| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 9 | 2023 | 697 | 2.450 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2023 | 108 | 2.400 |
Why?
|
| Kidney Neoplasms | 4 | 2023 | 166 | 2.310 |
Why?
|
| Lung Neoplasms | 13 | 2024 | 695 | 2.250 |
Why?
|
| Urinary Bladder Neoplasms | 14 | 2023 | 106 | 1.980 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 174 | 1.090 |
Why?
|
| Early Detection of Cancer | 10 | 2024 | 321 | 1.010 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 1669 | 0.850 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 356 | 0.830 |
Why?
|
| Cadherins | 7 | 2008 | 82 | 0.750 |
Why?
|
| Gene Expression | 2 | 2026 | 851 | 0.750 |
Why?
|
| Gene Expression Profiling | 8 | 2026 | 783 | 0.730 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 512 | 0.690 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.680 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2023 | 534 | 0.480 |
Why?
|
| Cell Movement | 6 | 2023 | 466 | 0.460 |
Why?
|
| Urethral Stricture | 3 | 2021 | 70 | 0.450 |
Why?
|
| Neoplasm Invasiveness | 13 | 2022 | 279 | 0.430 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 529 | 0.430 |
Why?
|
| Humans | 45 | 2026 | 64279 | 0.390 |
Why?
|
| DNA, Neoplasm | 3 | 2014 | 59 | 0.370 |
Why?
|
| Lichen Sclerosus et Atrophicus | 3 | 2021 | 20 | 0.370 |
Why?
|
| Middle Aged | 17 | 2026 | 17923 | 0.360 |
Why?
|
| Aged | 15 | 2026 | 14664 | 0.360 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2009 | 43 | 0.340 |
Why?
|
| Cell Line, Tumor | 10 | 2023 | 1494 | 0.330 |
Why?
|
| Male | 24 | 2026 | 30323 | 0.330 |
Why?
|
| Catechin | 2 | 2007 | 37 | 0.320 |
Why?
|
| Cell Proliferation | 3 | 2023 | 1001 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 423 | 0.290 |
Why?
|
| Tea | 2 | 2007 | 32 | 0.280 |
Why?
|
| Nephrectomy | 2 | 2020 | 93 | 0.280 |
Why?
|
| Biopsy | 4 | 2019 | 449 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 204 | 0.280 |
Why?
|
| Prognosis | 8 | 2022 | 1769 | 0.270 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 78 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2021 | 2049 | 0.260 |
Why?
|
| Disease Progression | 4 | 2020 | 1176 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2005 | 329 | 0.250 |
Why?
|
| Homeodomain Proteins | 2 | 2023 | 272 | 0.250 |
Why?
|
| Female | 18 | 2024 | 33382 | 0.250 |
Why?
|
| Kidney | 2 | 2020 | 455 | 0.240 |
Why?
|
| Prostate | 2 | 2018 | 91 | 0.240 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 91 | 0.240 |
Why?
|
| Penile Induration | 1 | 2026 | 6 | 0.240 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 421 | 0.240 |
Why?
|
| Penis | 1 | 2026 | 38 | 0.230 |
Why?
|
| Cohort Studies | 3 | 2021 | 2605 | 0.230 |
Why?
|
| Transfection | 4 | 2021 | 695 | 0.220 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 698 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 358 | 0.210 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2003 | 7 | 0.200 |
Why?
|
| Hospitalization | 2 | 2021 | 1368 | 0.200 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2023 | 20 | 0.200 |
Why?
|
| Carcinoma | 1 | 2004 | 129 | 0.200 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2021 | 52 | 0.200 |
Why?
|
| Administration, Intravesical | 1 | 2023 | 13 | 0.200 |
Why?
|
| Retrospective Studies | 10 | 2023 | 6742 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2007 | 3070 | 0.190 |
Why?
|
| Survival Analysis | 3 | 2021 | 587 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 128 | 0.190 |
Why?
|
| Urethra | 2 | 2021 | 76 | 0.190 |
Why?
|
| Lung | 3 | 2023 | 964 | 0.180 |
Why?
|
| High Mobility Group Proteins | 3 | 2007 | 24 | 0.180 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 5 | 0.170 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 140 | 0.170 |
Why?
|
| Mutation | 3 | 2016 | 2629 | 0.170 |
Why?
|
| Vascular Calcification | 1 | 2021 | 26 | 0.170 |
Why?
|
| Carcinoma, Lobular | 1 | 2001 | 26 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 1164 | 0.170 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 35 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2020 | 297 | 0.170 |
Why?
|
| Pectoralis Muscles | 1 | 2020 | 8 | 0.170 |
Why?
|
| Adult | 8 | 2026 | 17133 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 259 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1105 | 0.160 |
Why?
|
| Emphysema | 1 | 2020 | 38 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2023 | 265 | 0.160 |
Why?
|
| Trans-Activators | 2 | 2005 | 312 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 1213 | 0.160 |
Why?
|
| Repressor Proteins | 3 | 2007 | 348 | 0.150 |
Why?
|
| Cluster Analysis | 2 | 2017 | 263 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2482 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 5528 | 0.150 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 63 | 0.150 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 97 | 0.150 |
Why?
|
| Microarray Analysis | 2 | 2017 | 64 | 0.150 |
Why?
|
| Pneumonia | 1 | 2021 | 291 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 927 | 0.140 |
Why?
|
| Immunohistochemistry | 6 | 2019 | 901 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2010 | 36 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 320 | 0.130 |
Why?
|
| Mice | 6 | 2023 | 11003 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2007 | 217 | 0.130 |
Why?
|
| Blotting, Western | 6 | 2010 | 614 | 0.120 |
Why?
|
| Dasatinib | 1 | 2016 | 5 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 34 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2016 | 26 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2016 | 64 | 0.120 |
Why?
|
| Animals | 10 | 2023 | 20962 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 201 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 283 | 0.110 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2014 | 8 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 544 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 3 | 2005 | 205 | 0.100 |
Why?
|
| Catenins | 3 | 2007 | 14 | 0.100 |
Why?
|
| Wound Healing | 2 | 2005 | 192 | 0.100 |
Why?
|
| Surgical Flaps | 2 | 2005 | 117 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 709 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 216 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 373 | 0.100 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2003 | 16 | 0.090 |
Why?
|
| Neoplasms | 2 | 2022 | 1392 | 0.090 |
Why?
|
| Skin | 2 | 2005 | 386 | 0.090 |
Why?
|
| Young Adult | 2 | 2022 | 4781 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 391 | 0.080 |
Why?
|
| Neoplasm Transplantation | 2 | 2007 | 167 | 0.080 |
Why?
|
| Genes, Suppressor | 1 | 2010 | 7 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 2 | 2007 | 72 | 0.080 |
Why?
|
| Risk | 2 | 2021 | 379 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 2 | 2007 | 92 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2007 | 281 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2007 | 240 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2019 | 37 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2007 | 210 | 0.080 |
Why?
|
| Wnt Proteins | 2 | 2006 | 100 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2007 | 891 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2018 | 460 | 0.070 |
Why?
|
| Smoking | 2 | 2023 | 861 | 0.070 |
Why?
|
| Quinazolines | 1 | 2007 | 22 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2006 | 110 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2007 | 197 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2007 | 120 | 0.060 |
Why?
|
| Exons | 2 | 2007 | 201 | 0.060 |
Why?
|
| Probability | 2 | 2023 | 169 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 319 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2007 | 221 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2007 | 883 | 0.060 |
Why?
|
| Cell Division | 1 | 2007 | 454 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2005 | 18 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2026 | 28 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2005 | 21 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2006 | 948 | 0.060 |
Why?
|
| Butyrates | 1 | 2005 | 16 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 28 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 104 | 0.060 |
Why?
|
| beta Catenin | 2 | 2005 | 99 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2005 | 146 | 0.050 |
Why?
|
| Chromones | 1 | 2004 | 19 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2026 | 180 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2004 | 32 | 0.050 |
Why?
|
| Clone Cells | 1 | 2004 | 116 | 0.050 |
Why?
|
| Laminin | 1 | 2004 | 78 | 0.050 |
Why?
|
| Growth Substances | 1 | 2004 | 34 | 0.050 |
Why?
|
| Serine | 1 | 2004 | 91 | 0.050 |
Why?
|
| Imidazoles | 1 | 2004 | 84 | 0.050 |
Why?
|
| Morpholines | 1 | 2004 | 90 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2004 | 168 | 0.050 |
Why?
|
| Flavonoids | 1 | 2004 | 75 | 0.050 |
Why?
|
| Phenotype | 3 | 2018 | 1222 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1431 | 0.050 |
Why?
|
| Collagen | 1 | 2004 | 124 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2003 | 5 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 174 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2004 | 386 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 429 | 0.050 |
Why?
|
| Pyridines | 1 | 2004 | 114 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2003 | 46 | 0.050 |
Why?
|
| Schwann Cells | 1 | 2003 | 9 | 0.050 |
Why?
|
| Polyglycolic Acid | 1 | 2003 | 18 | 0.050 |
Why?
|
| Sciatic Nerve | 1 | 2003 | 29 | 0.050 |
Why?
|
| Peripheral Nerves | 1 | 2003 | 33 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 2003 | 38 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2003 | 75 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 45 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2010 | 1540 | 0.050 |
Why?
|
| Bronchi | 1 | 2022 | 84 | 0.050 |
Why?
|
| Transcriptome | 1 | 2026 | 396 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 5697 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2021 | 130 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 3318 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2022 | 138 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 73 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 321 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 171 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 153 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 67 | 0.040 |
Why?
|
| Polymers | 1 | 2003 | 327 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 218 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 390 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2005 | 625 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2005 | 802 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 292 | 0.040 |
Why?
|
| Weight Loss | 1 | 2020 | 276 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 652 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 856 | 0.030 |
Why?
|
| United States | 2 | 2021 | 7923 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1119 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2007 | 100 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 693 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1020 | 0.030 |
Why?
|
| Machine Learning | 1 | 2018 | 184 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 329 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 2019 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 874 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1570 | 0.030 |
Why?
|
| Rats | 3 | 2005 | 2005 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 58 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 1683 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 195 | 0.030 |
Why?
|
| gamma Catenin | 2 | 2005 | 6 | 0.030 |
Why?
|
| Desmoplakins | 2 | 2005 | 10 | 0.030 |
Why?
|
| Plasmids | 2 | 2006 | 293 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1162 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2096 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 869 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2005 | 165 | 0.030 |
Why?
|
| Genes, APC | 1 | 2014 | 11 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 49 | 0.030 |
Why?
|
| Epigenomics | 1 | 2014 | 62 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 2238 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 518 | 0.020 |
Why?
|
| Child | 1 | 2022 | 4583 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 294 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 6305 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2010 | 8 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Models, Biological | 2 | 2006 | 1187 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2009 | 209 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2007 | 17 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2007 | 19 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 668 | 0.020 |
Why?
|
| Cystectomy | 1 | 2007 | 35 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 93 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 210 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2006 | 11 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2007 | 517 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2005 | 16 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2006 | 260 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 375 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 57 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 490 | 0.010 |
Why?
|
| Tissue Survival | 1 | 2004 | 5 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2004 | 11 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 375 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 152 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 582 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 365 | 0.010 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2004 | 35 | 0.010 |
Why?
|
| Liposomes | 1 | 2004 | 107 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 240 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 333 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2055 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 151 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 324 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 1597 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1997 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1551 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 666 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 3726 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5342 | 0.010 |
Why?
|